Bio-Gene Technology Ltd (AU:BGT) — Market Cap & Net Worth
Market Cap & Net Worth: Bio-Gene Technology Ltd (BGT)
Bio-Gene Technology Ltd (AU:BGT) has a market capitalization of $4.96 Million (AU$7.02 Million) as of August 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28565 globally and #1522 in its home market, demonstrating a 35.29% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bio-Gene Technology Ltd's stock price AU$0.02 by its total outstanding shares 305061108 (305.06 Million). See BGT capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Bio-Gene Technology Ltd Market Cap History: 2017 to 2026
Bio-Gene Technology Ltd's market capitalization history from 2017 to 2026. Data shows change from $42.09 Million to $4.96 Million (-22.05% CAGR).
Bio-Gene Technology Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bio-Gene Technology Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.68x
Bio-Gene Technology Ltd's market cap is 11.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $42.09 Million | $6.32K | -$1.05 Million | 6664.15x | N/A |
| 2018 | $21.59 Million | $344.45K | -$2.83 Million | 62.67x | N/A |
| 2019 | $43.17 Million | $508.76K | -$1.92 Million | 84.85x | N/A |
| 2020 | $30.22 Million | $907.58K | -$1.93 Million | 33.30x | N/A |
| 2021 | $44.25 Million | $62.61K | -$2.40 Million | 706.74x | N/A |
| 2022 | $21.59 Million | $445.73K | -$2.91 Million | 48.43x | N/A |
| 2023 | $12.95 Million | $149.23K | -$3.10 Million | 86.78x | N/A |
| 2024 | $9.28 Million | $18.32K | -$2.41 Million | 506.64x | N/A |
| 2025 | $4.96 Million | $425.07K | -$2.58 Million | 11.68x | N/A |
Competitor Companies of BGT by Market Capitalization
Companies near Bio-Gene Technology Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Bio-Gene Technology Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Bio-Gene Technology Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Bio-Gene Technology Ltd's market cap moved from $42.09 Million to $ 4.96 Million, with a yearly change of -22.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$4.96 Million | 0.00% |
| 2025 | AU$4.96 Million | -46.51% |
| 2024 | AU$9.28 Million | -28.33% |
| 2023 | AU$12.95 Million | -40.00% |
| 2022 | AU$21.59 Million | -51.22% |
| 2021 | AU$44.25 Million | +46.43% |
| 2020 | AU$30.22 Million | -30.00% |
| 2019 | AU$43.17 Million | +100.00% |
| 2018 | AU$21.59 Million | -48.72% |
| 2017 | AU$42.09 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Bio-Gene Technology Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.96 Million USD |
| MoneyControl | $4.96 Million USD |
| MarketWatch | $4.96 Million USD |
| marketcap.company | $4.96 Million USD |
| Reuters | $4.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bio-Gene Technology Ltd
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more